Skip to main content

Table 2 Baseline demographic and clinical characteristics of the NUCs discontinuation patients treated by lamivudine, adefovir, entecavir, and telbivudine

From: Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative

Characteristic

LAM

ADV

ETV

LDT

Number. (%)

15 (22.7)

42 (63.6)

7 (10.6)

2 (3.0)

Age (Mean ±SD) - yr

34.1±13.0

35.3±10.6

36.1±14.0

33.5±10.6

  <29 - no.

4

9

2

1

  30-39 - no.

8

24

3

0

  >39 - no.

3

9

2

1

Man - no. (%)

14 (93.3)

30 (71.4)

4 (57.1)

2 (100)

ALT [Median (IQR)] - ULN

2.6 (1.2-3.5)

2.5 (1.3-6.6)

4.7 (2.7-14.0)

9.5 (3.9, 15.0)

HBV DNA - log10 IU/mL

6.3±1.6

5.3±1.3

5.5±0.8

7.0±2.2

HBsAg loss - no. (%)

2 (100)

0

0

0

  1. LAM, lamivudine; ADV, adefovir; ETV, entecavir; LDT, telbivudine.